系统化疗治疗晚期肝细胞癌的现状和研究进展

Current situation and research progress of systemic chemotherapy in the treatment of advanced hepatocellular carcinoma

原发性肝癌是我国高发、常见的恶性肿瘤,其主要病理类型为肝细胞癌(HCC)。由于HCC往往具有基础肝病,起病隐匿、进展迅速和早诊困难,确诊时大多数已达到局部晚期或者发生肝外转移,治疗棘手,疗效有限,预后很差。对于晚期HCC,系统化疗是临床上常用的姑息治疗手段。EACH研究的结果业已表明采用以奥沙利铂(OXA)为主的方案系统化疗,对于亚洲特别是我国的晚期HCC患者具有较好的客观疗效和一定的生存获益,成为继索拉非尼之后又一重要进展。因此,近年来,系统化疗治疗晚期HCC的研究已经成为HCC治疗领域的新热点。本文拟对OXA为主的方案系统化疗的现状与研究进展作一简要综述。

Primary liver cancer is a very common malignant tumor with especially higher incidence and special characters in China, which mainly consisted of hepatocellular carcinoma （HCC）. Because of its back- ground liver disease, hidden onset, rapid progress and difficulty of early diagnosis, most HCC patients have already reached local advanced stage or metastasis at diagnosis, and contributed to very tou,h treatment. and poor prognosis Systemic chemotherapy is commonly used in clinic-1 ,,.~.. ; very bad response ~ ＂ ~ as a patnauve method for such patients. According to the results of EACH study, it has been shown that systemic chemotherapy based on oxaliplatin （OXA） may have a higher objective response and tendency of improving survival time for Asian and especially Chinese ad- vanced HCC patients. Thus systemic chemotherapy based on OXA already became another important treatment op- tion after sorafenib. In recent years, systemic chemotherapy with OXA for advanced HCC has become the hot spot in the field of HCC research. This paper comprehensively reviewed current situation and progress of the related studies.